El nuevo ensayo de coagulación dependiente de factores de tejido en el lado de la cama permite una mejor evaluación

M B Holmes1, D J Schneider, M G Hayes

  • 1Department of Medicine, University of Vermont College of Medicine, Burlington, USA.

Circulation
|October 25, 2000
PubMed
Resumen

Un nuevo ensayo que utiliza el factor de tejido en sangre completa mejora la evaluación de las combinaciones de fármacos antiplaquetarios y antitrombóticos. Este método sensible ayuda a optimizar la dosificación del medicamento y monitorear la eficacia del tratamiento.

Videos de Conceptos Relacionados

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K